Drug Giant Pfizer to Build $100 Million R&D Center in Boston
06/13/2011
The new world headquarters for the Centers for Therapeutic Innovation will house 40 employees and Pfizer's drug-development activity, and complement the company's existing offices in Cambridge.
Work at the facility will be done in collaboration with various renowned Boston-based medical and research centers. They include: the University of Massachusetts Medical School, Tufts Medical School, Beth Israel Deaconess Medical Center, Children's Hospital Boston, Partners Healthcare, Harvard University, Boston University and Tufts University. Pfizer indicated in a press release these partners could earn "milestone payments" for successful development of the "next generation of medicines."
"These partnerships allow leading medical and clinical experts to join with Pfizer's highly-skilled scientists and advanced drug development capabilities to speed the translation of innovative science into medicines for patients," said Jose Carlos Gutierrez-Ramos, Ph.D., senior VP and head of BioTherapeutics Research and Development for Pfizer. "Our ultimate goal is to bridge the gap between scientific discovery and the delivery of promising candidates to the pipeline."
Project Announcements
JGA Space and Defense Expands Huntersville, North Carolina, Operations
12/05/2025
SODECIA-AAPICO Plans Orangeburg, South Carolina, Manufacturing Operations
12/05/2025
France-Based Satys Establishes Melbourne, Florida, Operations
12/05/2025
AstraZeneca Expands Frederick-Gaithersburg Maryland, Manufacturing Operations
11/29/2025
Foxconn Expands Mount Pleasant, Wisconsin, Manufacturing Operations
11/28/2025
France-Based CITEL America Plans Hillsborough, North Carolina, Operations
11/28/2025
Most Read
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025
-
2025’s Top States for Business: How the Winners Are Outpacing the Rest
Q3 2025
-
Rethinking Auto Site Strategy in the Age of Tariffs and Powertrain Shifts
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
How Canada Stays Competitive
Q3 2025
-
America’s Aerospace Reboot
Q3 2025